dc.contributor.author | Wang, Qiao-Li | |
dc.contributor.author | Santoni, Giola | |
dc.contributor.author | Ness-Jensen, Eivind | |
dc.contributor.author | Lagergren, Jesper | |
dc.contributor.author | Xie, Shao-Hua | |
dc.date.accessioned | 2020-02-12T08:01:19Z | |
dc.date.available | 2020-02-12T08:01:19Z | |
dc.date.created | 2020-01-20T22:22:08Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | American Journal of Gastroenterology. 2020, 115 (1), 73-78. | nb_NO |
dc.identifier.issn | 0002-9270 | |
dc.identifier.uri | http://hdl.handle.net/11250/2641178 | |
dc.description.abstract | 4 ABSTRACT ObjectivesEsophageal cancer is a highly fatal malignant neoplasm, with two etiologically different histological types. A large prospective study is expected to elucidate the specific risk of the 90% subtype of esophageal cancer, esophageal squamous cell carcinoma, with metformin therapy. This study aims to determine the association between metformin use and incident esophageal squamous cell carcinoma risk. MethodsThis was a nationwide population-based prospective cohort study conducted inSwedenin 2005-2015.Among 8.4 million participants identified in the cohort, 411,603 (5%) were metformin users. The users were compared with 10 times as many frequency-matched non-users of metformin (n=4,116,030) by age and sex.Metformin use was treated as a time-varying variate and multivariable cause-specific proportional hazards model was used to calculate hazard ratios (HR) with 95% confidence intervals (CI) for esophageal squamous cell carcinoma, adjusted for age, sex, calendar year, residence area, tobacco smoking, alcohol overconsumption, and use of non-steroidal anti-inflammatory drugs or statins.ResultsThe incidence rates of esophageal squamous cell carcinoma were 3.5 per 100,000 person-years among the metformin users and 5.3 per 100,000 person-years in the non-users. Metformin users overall were at a decreased risk of esophageal squamous cell carcinoma compared with non-users (HR 0.68, 95% CI 0.54-0.85). The decrease in risk was more pronounced in new metformin users (HR 0.44, 95% CI 0.28-0.64) and participants aged 60-69 years (HR 0.45, 95% CI 0.31-0.66).ConclusionsMetformin use decreases the risk of developing esophageal squamous cell carcinoma | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Lippincott, Williams & Wilkins | nb_NO |
dc.title | Association Between Metformin Use and Risk of Esophageal Squamous Cell Carcinoma in a Population-Based Cohort Study | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | acceptedVersion | nb_NO |
dc.source.pagenumber | 73-78 | nb_NO |
dc.source.volume | 115 | nb_NO |
dc.source.journal | American Journal of Gastroenterology | nb_NO |
dc.source.issue | 1 | nb_NO |
dc.identifier.doi | 10.14309/ajg.0000000000000478 | |
dc.identifier.cristin | 1778661 | |
dc.description.localcode | © 2020. This is the authors' accepted and refereed manuscript to the chapter. Locked until 1.01.2021 due to copyright restrictions. The final authenticated version is available online at: 10.14309/ajg.0000000000000478 | nb_NO |
cristin.unitcode | 194,65,20,15 | |
cristin.unitname | Helseundersøkelsen i Nord-Trøndelag | |
cristin.ispublished | true | |
cristin.fulltext | postprint | |
cristin.qualitycode | 1 | |